Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNK6105 in hospitalized patients with cirrhosis and hepatic encephalopathy
NCT04128462Phase 3Withdrawn
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of ornithine phenylacetate in hepatic encephalopathy (HE), sponsored by Mallinckrodt Pharmaceuticals. Planned start Nov 2021; status: withdrawn.
02
Drugs
ornithine phenylacetate
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT04128462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128462.